JP2022523719A - Aavキャプシドの転写依存性定方向進化を使用するための方法 - Google Patents
Aavキャプシドの転写依存性定方向進化を使用するための方法 Download PDFInfo
- Publication number
- JP2022523719A JP2022523719A JP2021544346A JP2021544346A JP2022523719A JP 2022523719 A JP2022523719 A JP 2022523719A JP 2021544346 A JP2021544346 A JP 2021544346A JP 2021544346 A JP2021544346 A JP 2021544346A JP 2022523719 A JP2022523719 A JP 2022523719A
- Authority
- JP
- Japan
- Prior art keywords
- aav
- cap
- seq
- concatenated
- orf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 210000000234 capsid Anatomy 0.000 title abstract description 63
- 239000013607 AAV vector Substances 0.000 claims abstract description 66
- 238000013518 transcription Methods 0.000 claims abstract description 12
- 230000035897 transcription Effects 0.000 claims abstract description 12
- 241000702421 Dependoparvovirus Species 0.000 claims description 243
- 239000013598 vector Substances 0.000 claims description 87
- 101150044789 Cap gene Proteins 0.000 claims description 73
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 56
- 108020005544 Antisense RNA Proteins 0.000 claims description 56
- 102000039446 nucleic acids Human genes 0.000 claims description 54
- 108020004707 nucleic acids Proteins 0.000 claims description 54
- 150000007523 nucleic acids Chemical class 0.000 claims description 54
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 50
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 238000003757 reverse transcription PCR Methods 0.000 claims description 28
- 230000000692 anti-sense effect Effects 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 24
- 108020004999 messenger RNA Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 238000004806 packaging method and process Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 12
- 238000012163 sequencing technique Methods 0.000 claims description 11
- 230000008488 polyadenylation Effects 0.000 claims description 10
- 108091081021 Sense strand Proteins 0.000 claims description 9
- 238000002864 sequence alignment Methods 0.000 claims description 7
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 6
- 108090000565 Capsid Proteins Proteins 0.000 claims description 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 6
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 3
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 241000701945 Parvoviridae Species 0.000 claims 17
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 241000649045 Adeno-associated virus 10 Species 0.000 claims 2
- 241000649046 Adeno-associated virus 11 Species 0.000 claims 2
- 241000649047 Adeno-associated virus 12 Species 0.000 claims 2
- 241000300529 Adeno-associated virus 13 Species 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 75
- 238000010361 transduction Methods 0.000 abstract description 44
- 230000026683 transduction Effects 0.000 abstract description 44
- 210000004556 brain Anatomy 0.000 abstract description 39
- 210000002569 neuron Anatomy 0.000 abstract description 36
- 230000001537 neural effect Effects 0.000 abstract description 22
- 238000001727 in vivo Methods 0.000 abstract description 14
- 230000001419 dependent effect Effects 0.000 abstract description 11
- 238000001990 intravenous administration Methods 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 212
- 108700026244 Open Reading Frames Proteins 0.000 description 95
- 101710187887 Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 61
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 241000282560 Macaca mulatta Species 0.000 description 27
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 230000002093 peripheral effect Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 210000000056 organ Anatomy 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 238000012795 verification Methods 0.000 description 19
- 239000000370 acceptor Substances 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 16
- 210000005013 brain tissue Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 229930040373 Paraformaldehyde Natural products 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 229920002866 paraformaldehyde Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108091035707 Consensus sequence Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000013227 male C57BL/6J mice Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000002463 transducing effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000002055 immunohistochemical effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000037432 silent mutation Effects 0.000 description 5
- 238000012385 systemic delivery Methods 0.000 description 5
- 108010051219 Cre recombinase Proteins 0.000 description 4
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 241000209094 Oryza Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000005156 neurotropism Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000010820 immunofluorescence microscopy Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000000370 laser capture micro-dissection Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000124740 Bocaparvovirus Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- -1 brain Chemical compound 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 102000056115 human SYN1 Human genes 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 210000002637 putamen Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000121268 Erythroparvovirus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241001661355 Synapsis Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013228 adult male C57BL/6J mice Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 206010001902 amaurosis Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000002975 pon Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000003814 preoptic area Anatomy 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本発明は、アメリカ国立衛生研究所(National Institutes of Health)/アメリカ国立神経疾患・脳卒中研究所(National Institute of Neurological Disorders and Stroke)によって与えられた第NS088399号の下の政府支援で実施された。政府は本発明において一定の権利を有している。
Claims (41)
- 核酸であって、該核酸は、
ITR配列によって隣接されるパルボウイルス科ゲノムであって、該パルボウイルス科ゲノムは、パルボウイルス科イントロン、パルボウイルス科キャップ遺伝子、および第1配向の第1ポリアデニル化シグナルを含む、パルボウイルス科ゲノムと、
アデノウイルスのヘルパー機能の存在下でパルボウイルス科キャップ遺伝子の発現を推進させる前記第1配向の第1プロモーターと、
前記第1配向に対してアンチセンスである第2配向の第2プロモーターおよび第2ポリアデニル化シグナルであって、前記第2ポリアデニル化シグナルは、パルボウイルス科キャップ遺伝子のアンチセンスmRNA転写の終結を引き起こす位置に位置する、第2配向の第2プロモーターおよび第2ポリアデニル化シグナルと、を含む、核酸。 - 前記第2プロモーターは、細胞型特異的プロモーターである、請求項1に記載の核酸。
- 前記第2プロモーターは、ユビキタスプロモーターである、請求項1に記載の核酸。
- 前記パルボウイルス科ゲノムは、AAVイントロンおよびAAVキャップ遺伝子を含むAAVゲノムである、請求項1~3のいずれかに記載の核酸。
- 前記AAVキャップ遺伝子は、野生型のAAVキャップ遺伝子である、請求項4に記載の核酸。
- 前記AAVキャップ遺伝子の配列は、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12、AAV13、または他の天然のAAV単離キャップ遺伝子配列である、請求項5に記載の核酸。
- 前記AAVキャップ遺伝子は、組み換えAAVキャップ遺伝子である、請求項4に記載の核酸。
- 前記AAVキャップ遺伝子は、多様なAAVキャップ遺伝子のライブラリーの1つである、請求項4に記載の核酸。
- 請求項4に記載の複数の核酸を含む核酸ライブラリーであって、前記核酸は、複数の固有のAAVキャップ遺伝子配列を含む、核酸ライブラリー。
- 前記核酸ライブラリーは、約102、103、104、105、106、107または108を上回る固有のAAVキャップ遺伝子配列を含む、請求項9に記載の核酸ライブラリー。
- 前記第2配向の対象遺伝子をさらに含む、請求項1~8のいずれかに記載の核酸。
- 前記第2ポリアデニル化シグナルは、AAVイントロン内に位置する、請求項4~8または11のいずれかに記載の核酸。
- 前記第2ポリアデニル化シグナルは、キャップ遺伝子が第1配向の完全長のキャプシドタンパク質に正確に翻訳され、およびキャップ遺伝子が、完全長のAAVキャップ遺伝子コード配列を含むアンチセンスmRNAへと正確に転写されるように、位置する、請求項4~8または11のいずれかに記載の核酸。
- 異なるキャップ遺伝子配列を有する少なくとも1つの他のAAVベクターと比較して、対象組織から細胞を形質導入する能力が増大したキャップ遺伝子配列を有するAAVベクターを同定する方法であって、該方法は、
請求項9または10に記載の核酸ライブラリーをAAVパッケージング細胞株へと導入し、およびパッケージング細胞株から第1回AAV TRADEベクターライブラリーを回収させることによって第1回AAV TRADEベクターライブラリーを調製する工程と、
第1回AAV TRADEベクターライブラリーを1つ以上の動物に注入する工程と、
動物の対象組織の細胞内で富化されるAAVベクターのキャップ遺伝子配列を回収する工程と、
前記豊化されたAAVベクターの回収されたキャップ遺伝子配列を含む第2回のAAV TRADE核酸ライブラリーを調製し、このライブラリーをAAVパッケージング細胞株へ導入し、パッケージング細胞株から第2回AAV TRADEベクターライブラリーを回収する工程と、
第2回のAAV TRADEベクターライブラリーを1つ以上の動物に注入し、および動物の対象組織の細胞内で豊化されるキャップ遺伝子配列を回収することによって第2回の富化を実施する工程と、
富化されたAAVキャップ遺伝子配列を、第1回富化後、第2回富化後、およびその後任意の回の富化後に同定する工程と、を含む方法。 - AAV TRADEベクター、またはAAV TRADEベクターライブラリーを産生する方法であって、該方法は、
請求項4~8または11~13のいずれかに記載の核酸、または請求項9または10に記載の核酸ライブラリーを、AAVパッケージング細胞株へと導入する工程と、AAV TRADEベクターまたはAAV TRADEベクターライブラリーをパッケージング細胞株から回収する工程と、を含む方法。 - 対象組織の細胞を形質導入する能力が増大したAAVベクターの新しいキャップ遺伝子の配列を決定する方法であって、該方法は、
請求項14に記載の方法でAAVベクターを同定する工程と、
キャップ遺伝子配列を含むアンチセンスmRNAを回収する工程と、
新しいキャップ遺伝子配列を決定する工程と、を含む方法。 - 前記アンチセンスmRNAは、RT-PCRを使用して回収される、請求項16に記載の方法。
- 前記キャップ遺伝子配列を決定する工程をさらに含む、請求項16または17に記載の方法。
- 請求項4~8または11~13のいずれかに記載の核酸を含む、AAVベクター。
- 核酸であって、該核酸は、
ITR配列によって隣接されるパルボウイルス科ゲノムであって、該パルボウイルス科ゲノムは、パルボウイルス科イントロン、パルボウイルス科キャップ遺伝子、および第1配向の第1ポリアデニル化シグナルを含む、パルボウイルス科ゲノムと、
アデノウイルスのヘルパー機能の存在下でパルボウイルス科キャップ遺伝子の発現を推進させる前記第1配向の第1プロモーターと、
アデノウイルスのヘルパー機能の不在下でパルボウイルス科キャップ遺伝子の発現を推進させる前記第1配向の第2プロモーターと、を含む核酸。 - 前記第2プロモーターは、細胞型特異的プロモーターである、請求項20に記載の核酸。
- 前記第2プロモーターは、ユビキタスプロモーターである、請求項20に記載の核酸。
- 前記パルボウイルス科キャップ遺伝子は、野生型のAAVキャップ遺伝子である、請求項20~22のいずれかに記載の核酸。
- 前記AAVキャップ遺伝子配列は、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12、AAV13、または他の天然のAAV単離キャップ遺伝子配列である、請求項23に記載の核酸。
- 前記パルボウイルス科キャップ遺伝子は、組み換えAAVキャップ遺伝子である、請求項20~22のいずれかに記載の核酸。
- 前記パルボウイルス科キャップ遺伝子は、多様なAAVキャップ遺伝子のライブラリーの1つである、請求項20~25のいずれかに記載の核酸。
- 請求項20に記載の複数の核酸を含む核酸ライブラリーであって、前記核酸は、複数の固有のパルボウイルス科キャップ遺伝子配列を含む、核酸ライブラリー。
- 前記核酸ライブラリーは、約102、103、104、105、106、107または108を上回る固有のAAVキャップ遺伝子配列を含む、請求項27に記載の核酸ライブラリー。
- 対象遺伝子をさらに含む、請求項20~26のいずれかに記載の核酸。
- 異なるキャップ遺伝子配列を有する少なくとも1つの他のAAVベクターと比較して、対象組織から細胞を形質導入する能力が増大したキャップ遺伝子配列を有するAAVベクターを同定する方法であって、該方法は、
請求項27または28に記載の核酸ライブラリーをAAVパッケージング細胞株へと導入し、およびパッケージング細胞株から第1回AAV TRADEベクターライブラリーを回収することによって第1回AAV TRADEベクターライブラリーを調製する工程と、
第1回AAV TRADEベクターライブラリーを1つ以上の動物に注入する工程と、
動物に対象組織の細胞内で富化されるAAVベクターのキャップ遺伝子配列を回収する工程と、
前記豊化されたAAVベクターのキャップ遺伝子配列を含む第2回のAAV TRADE核酸ライブラリーを調製し、このライブラリーをAAVパッケージング細胞株へ導入し、パッケージング細胞株から第2回AAV TRADEベクターライブラリーを回収する工程と、
第2回のAAV TRADEベクターライブラリーを1つ以上の動物に注入し、および動物に対象組織の細胞内で豊化されるキャップ遺伝子配列を回収することによって第2回の富化を実施する工程と、
富化されたAAVキャップ遺伝子配列を、第1回富化後、第2回富化後、およびその後任意の回の富化後に同定する工程と、を含む方法。 - AAV TRADEベクター、またはAAV TRADEベクターライブラリーを産生する方法であって、該方法は、
請求項23~26または29のいずれかに記載の核酸、または請求項27または28に記載の核酸ライブラリーを、AAVパッケージング細胞株へと導入する工程と、AAV TRADEベクターまたはAAV TRADEベクターライブラリーをパッケージング細胞株から回収する工程と、を含む方法。 - 対象組織の細胞を形質導入する能力が増大したAAVベクターの新しいキャップ遺伝子の配列を決定する方法であって、該方法は、
請求項30に記載の方法でAAVベクターを同定する工程と、
キャップ遺伝子配列を含むセンスmRNAを回収する工程と、
新しいキャップ遺伝子配列を決定する工程と、を含む方法。 - 前記センスmRNAは、RT-PCRを使用して回収する、請求項32に記載の方法。
- 前記キャップ遺伝子配列を決定する工程をさらに含む、請求項32または33に記載の方法。
- 請求項23~26または29のいずれかに記載の核酸を含む、AAVベクター。
- 前記第2配向の少なくとも1つのmRNAスプライシング抑制突然変異をさらに含む、請求項1~8または11~13のいずれかに記載の核酸。
- 前記少なくとも1つのmRNAスプライシング抑制突然変異は、スプライスドナーおよび/またはスプライスアクセプター部位の10のヌクレオチド内に位置する1つ以上のヌクレオチドの変質を含む、請求項36に記載の核酸。
- 前記変質は、AAVキャップ遺伝子によってコードされたアミノ酸配列を変更しない、請求項36または37に記載の核酸。
- AAVキャップORF配列であって、スプライシングドナー部位のエキソン-イントロン連結の1つ以上の以下の突然変異:
AAV1 VP1キャップORF 1009-CTTAC(連結)CAGCA-1018*(配列番号:199)
AAV3 VP1キャップORF 1006-CTTAC(連結)CAGCA-1015*(配列番号:199)
AAV1 VP1キャップORF 1228-TTTAC(連結)CTTCA-1237(配列番号:200)
AAV3 VP1キャップORF 1237-TATAC(連結)CTTCG-1246(配列番号:201)
AAV1 VP1キャップORF 1331-ATTAC(連結)CTGAA-1340(配列番号:202)
AAV1 VP1キャップORF 1434-GCTAC(連結)CTGGA-1443(配列番号:203)
AAV1 VP1キャップORF 1502-TTTAC(連結)CTGGA-1510(配列番号:204)
AAV1 VP1キャップORF 1803-ATTAC(連結)CTGGC-1812(配列番号:205)
AAV3 VP1キャップORF 1803-CTTAC(連結)CTGGC-1812(配列番号:206)
AAV1 VP1キャップORF 1835-TGTAC(連結)CTGCA-1844(配列番号:207)
AAV1 VP1キャップORF 2189-GTTAC(連結)CTTAC-2198(配列番号:208)
AAV9 VP1キャップORF 2189-GATAC(連結)CTGAC-2198(配列番号:209)
AAV1 VP1キャップORF 2194-CTTAC(連結)CCGTC-2203(配列番号:210)
AAV3 VP1はORF 2194-CTCAC(連結)ACGAA-2203(配列番号:211)
(*ヌクレオチド番号は異なるが、それらは配列アラインメントにおけるAAVキャップORFの対応するヌクレオチドである。)を含む、AAVキャップORF配列。 - AAVキャップORF配列であって、スプライシングドナー部位のエキソン-イントロン連結の1つ以上の以下の突然変異:
AAV1 VP1キャップORF 305-AGCGT(連結)CTGCA-314(配列番号:212)
AAV1 VP1キャップORF 414-GGCTC(連結)CTGGA-423(配列番号:213)
AAV3 VP1キャップORF 414-GGCTC(連結)CTGGA-423(配列番号:213)
AAV1 VP1キャップORF 495-GCCCG(連結)CTAAA-504(配列番号:214)
AAV9 VP1キャップORF 495-GCCCG(連結)CTAAA-504(配列番号:214)
AAV3 VP1キャップORF 1133-TCACC(連結)CTGAA-1142(配列番号:215)
AAV1 VP1キャップORF 1181-ACTGC(連結)CTGGA-1190(配列番号:216)
AAV1 VP1キャップORF 1331-ATTAC(連結)CTGAA-1340**(配列番号:202)
AAV3 VP1キャップORF 1328-ACTAC(連結)CTGAA-1337**(配列番号:217)
AAV1 VP1キャップORF 1464-CGTTT(連結)CTAAA-1473(配列番号:218)
AAV1 VP1キャップORF 1653-AAACA(連結)CTGCA-1662(配列番号:219)
AAV1 VP1キャップORF 2054-GGGAG(連結)CTGCA-2063(配列番号:220)
AAV3 VP1キャップORF 2054-GGGAG(連結)CTACA-2063(配列番号:463)
(**ヌクレオチド番号は異なっても、それらは配列アラインメントにおけるAAVキャップORFの対応するヌクレオチドである。)を含む、AAVキャップORF配列。 - AAVキャップORF配列であって、スプライシングドナーまたはスプライシングアクセプター部位のエキソン-イントロン連結の1つ以上の以下の突然変異:
スプライスドナー
AAV1 VP1キャップORF 1009-CTTAC(連結)CAGCA-1018*(配列番号:199)
AAV3 VP1キャップORF 1006-CTTAC(連結)CAGCA-1015*(配列番号:199)
AAV1 VP1キャップORF 1228-TTTAC(連結)CTTCA-1237(配列番号:200)
AAV3 VP1キャップORF 1237-TATAC(連結)CTTCG-1246(配列番号:201)
AAV1 VP1キャップORF 1331-ATTAC(連結)CTGAA-1340(配列番号:202)
AAV1 VP1キャップORF 1434-GCTAC(連結)CTGGA-1443(配列番号:203)
AAV1 VP1キャップORF 1502-TTTAC(連結)CTGGA-1510(配列番号:204)
AAV1 VP1キャップORF 1803-ATTAC(連結)CTGGC-1812(配列番号:205)
AAV3 VP1キャップORF 1803-CTTAC(連結)CTGGC-1812(配列番号:206)
AAV1 VP1キャップORF 1835-TGTAC(連結)CTGCA-1844(配列番号:207)
AAV1 VP1キャップORF 2189-GTTAC(連結)CTTAC-2198(配列番号:208)
AAV9 VP1キャップORF 2189-GATAC(連結)CTGAC-2198(配列番号:209)
AAV1 VP1キャップORF 2194-CTTAC(連結)CCGTC-2203(配列番号:210)
AAV3 VP1キャップORF 2194-CTCAC(連結)ACGAA-2203(配列番号:211)
スプライスアクセプター
AAV1 VP1キャップORF 305-AGCGT(連結)CTGCA-314(配列番号:212)
AAV1 VP1キャップORF 414-GGCTC(連結)CTGGA-423(配列番号:213)
AAV3 VP1キャップORF 414-GGCTC(連結)CTGGA-423(配列番号:213)
AAV1 VP1キャップORF 495-GCCCG(連結)CTAAA-504(配列番号:214)
AAV9 VP1キャップORF 495-GCCCG(連結)CTAAA-504(配列番号:214)
AAV3 VP1キャップORF 1133-TCACC(連結)CTGAA-1142(配列番号:215)
AAV1 VP1キャップORF 1181-ACTGC(連結)CTGGA-1190(配列番号:216)
AAV1 VP1キャップORF 1331-ATTAC(連結)CTGAA-1340**(配列番号:202)
AAV3 VP1キャップORF 1328-ACTAC(連結)CTGAA-1337**(配列番号:217)
AAV1 VP1キャップORF 1464-CGTTT(連結)CTAAA-1473(配列番号:218)
AAV1 VP1キャップORF 1653-AAACA(連結)CTGCA-1662(配列番号:219)
AAV1 VP1キャップORF 2054-GGGAG(連結)CTGCA-2063(配列番号:220)
AAV3 VP1キャップORF 2054-GGGAG(連結)CTACA-2063(配列番号:463)を含む、AAVキャップORF配列。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962799603P | 2019-01-31 | 2019-01-31 | |
US62/799,603 | 2019-01-31 | ||
PCT/US2020/016273 WO2020160508A1 (en) | 2019-01-31 | 2020-01-31 | Methods for using transcription-dependent directed evolution of aav capsids |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022523719A true JP2022523719A (ja) | 2022-04-26 |
JPWO2020160508A5 JPWO2020160508A5 (ja) | 2023-02-07 |
Family
ID=71841691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021544346A Pending JP2022523719A (ja) | 2019-01-31 | 2020-01-31 | Aavキャプシドの転写依存性定方向進化を使用するための方法 |
Country Status (8)
Country | Link |
---|---|
US (5) | US20230193315A1 (ja) |
EP (1) | EP3917566A4 (ja) |
JP (1) | JP2022523719A (ja) |
KR (1) | KR20210130158A (ja) |
CN (1) | CN113924115A (ja) |
AU (1) | AU2020216480A1 (ja) |
CA (1) | CA3128230A1 (ja) |
WO (1) | WO2020160508A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113924115A (zh) | 2019-01-31 | 2022-01-11 | 俄勒冈健康与科学大学 | 用于aav衣壳的使用转录依赖性定向进化的方法 |
EP4126910A1 (en) * | 2020-04-01 | 2023-02-08 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
KR20230022175A (ko) | 2020-05-13 | 2023-02-14 | 보이저 테라퓨틱스, 인크. | Aav 캡시드의 향성 방향변경 |
WO2023034775A1 (en) | 2021-08-30 | 2023-03-09 | Avachrome, Inc. | Aavr knockout mouse in combination with human liver chimerism and methods of use and production of the same |
WO2023060272A2 (en) * | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
WO2023183304A2 (en) * | 2022-03-21 | 2023-09-28 | Capsigen Inc. | Transcription-dependent directed evolution of aav capsids having enhanced tropism |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
US6924128B2 (en) * | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
WO1996017947A1 (en) * | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
US5652224A (en) | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
JPH11507231A (ja) | 1995-06-07 | 1999-06-29 | イェール ユニバーシティ | アデノ関連ウイルスベクターの経口送達 |
US5866552A (en) | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
IL128736A0 (en) | 1996-09-06 | 2000-01-31 | Univ Pennsylvania | Methods using cre-lox for production of recombinant adeno-associated viruses |
FR2756297B1 (fr) | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | Procede de production de virus recombinants |
AU8672198A (en) | 1997-07-31 | 1999-02-22 | Chiron Corporation | Method enabling readministration of aav vector via immunosuppression of host |
US6251677B1 (en) | 1997-08-25 | 2001-06-26 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
EP1015619A1 (en) | 1997-09-19 | 2000-07-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
WO2000028004A1 (en) | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
US6387368B1 (en) | 1999-02-08 | 2002-05-14 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6498244B1 (en) | 1999-05-28 | 2002-12-24 | Cell Genesys, Inc. | Adeno-associated virus capsid immunologic determinants |
US6399385B1 (en) | 1999-09-29 | 2002-06-04 | The Trustees Of The University Of Pennsylvania | Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor |
WO2001077350A2 (en) * | 2000-04-07 | 2001-10-18 | Large Scale Biology Corporation | Compositions and methods for inhibiting gene expression |
JP2004501113A (ja) | 2000-06-01 | 2004-01-15 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 組み換えパルボウィルスベクターの制御放出のための方法および配合物 |
US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
EP1373527A1 (en) * | 2001-04-06 | 2004-01-02 | CropDesign N.V. | The use of double and opposite recombination sites for the single step cloning of two dna segments |
US7344872B2 (en) | 2001-06-22 | 2008-03-18 | The Trustees Of The University Of Pennsylvania | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
JP2004538005A (ja) | 2001-08-08 | 2004-12-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | シアル酸に結合するタンパク質を有するウイルスベクターの精製法 |
NZ600121A (en) | 2001-11-13 | 2013-12-20 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
NZ550416A (en) | 2001-11-21 | 2008-06-30 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
AU2002360291A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
AU2002359284A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
DE60310297T2 (de) | 2002-04-29 | 2007-06-06 | Trustees Of The University Of Pennsylvania | Methode für die direkte Gewinnung und Amplifikation von integrierten Viren aus zellulärer Gewebe-DNA |
PL1633772T3 (pl) | 2003-06-19 | 2016-10-31 | Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie | |
US7491508B2 (en) | 2003-06-20 | 2009-02-17 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
JP5054975B2 (ja) | 2003-09-30 | 2012-10-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス(aav)の同源系統群、配列、それらを含有するベクターおよびそれらの用途 |
WO2005072364A2 (en) | 2004-01-27 | 2005-08-11 | University Of Florida | A modified baculovirus expression system for production of pseudotyped raav vector |
EP1742668B1 (en) | 2004-04-28 | 2011-02-09 | The Trustees of The University of Pennsylvania | Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
JP5702519B2 (ja) | 2005-04-07 | 2015-04-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Aavベクターの機能を上げる方法 |
EP1979485A2 (en) | 2006-01-31 | 2008-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
US8129510B2 (en) | 2006-03-30 | 2012-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | Minigene expression cassette |
ES2400235T3 (es) | 2006-04-28 | 2013-04-08 | The Trustees Of The University Of Pennsylvania | Método de producción escalable de AAV |
US8945918B2 (en) * | 2006-08-24 | 2015-02-03 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
BRPI0822651A2 (pt) | 2007-11-28 | 2014-10-14 | Univ Pennsylvania | Subfamília b de adenovírus sadv-28, -27, 29, -32, -33 e -35 de símio e seus usos |
MX2010005860A (es) | 2007-11-28 | 2010-06-22 | Univ Pennsylvania | Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos. |
CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
CN102016011B (zh) | 2008-03-04 | 2013-12-11 | 宾夕法尼亚大学托管会 | 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用 |
US8940290B2 (en) | 2008-10-31 | 2015-01-27 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof |
EP2435559A1 (en) | 2009-05-29 | 2012-04-04 | The Trustees Of The University Of Pennsylvania | Simian adenovirus 41 and uses thereof |
US8445454B2 (en) | 2009-10-23 | 2013-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Use on minicircle vectors for cardiac gene therapy |
US20130035472A1 (en) * | 2010-03-17 | 2013-02-07 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
US8628966B2 (en) * | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
WO2012057363A1 (ja) * | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
WO2012064960A2 (en) * | 2010-11-10 | 2012-05-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
AU2011332025B2 (en) | 2010-11-23 | 2015-06-25 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof |
ES2724800T3 (es) | 2011-02-17 | 2019-09-16 | Univ Pennsylvania | Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9 |
US9169299B2 (en) | 2011-08-24 | 2015-10-27 | The Board Of Trustees Of The Leleand Stanford Junior University | AAV capsid proteins for nucleic acid transfer |
AU2013262626B2 (en) | 2012-05-18 | 2018-11-29 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof |
US9770011B2 (en) | 2012-09-29 | 2017-09-26 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
KR102346455B1 (ko) | 2013-03-15 | 2022-01-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Mpsi 치료를 위한 조성물 및 방법 |
US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
PT3116900T (pt) | 2014-03-09 | 2020-10-08 | Univ Pennsylvania | Composições úteis no tratamento da deficiência de ornitina transcarbamilase (otc) |
KR20160135729A (ko) | 2014-03-21 | 2016-11-28 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 뉴클레아제 없는 게놈 편집 |
US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
CN106470736B (zh) | 2014-05-13 | 2021-05-28 | 宾夕法尼亚州大学信托人 | 包括表达双抗体构建体的aav的组合物及其用途 |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
CA2966620A1 (en) | 2014-11-05 | 2016-05-12 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
CA3014637A1 (en) | 2016-02-16 | 2017-08-24 | Mark A. Kay | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
CN109476707B (zh) | 2016-05-13 | 2022-12-02 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和其使用方法 |
KR102392236B1 (ko) | 2016-05-18 | 2022-05-03 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
WO2018119330A2 (en) * | 2016-12-22 | 2018-06-28 | Oregon Health & Science University | Adeno associated viral vectors |
WO2019079496A2 (en) | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | FULLY HUMAN ANTIBODY-BASED THERAPEUTIC AGENTS HAVING POST-TRANSLATION MODIFICATION |
AU2019354995A1 (en) | 2018-10-02 | 2021-05-13 | Voyager Therapeutics, Inc. | Redirection of tropism of AAV capsids |
CN113924115A (zh) | 2019-01-31 | 2022-01-11 | 俄勒冈健康与科学大学 | 用于aav衣壳的使用转录依赖性定向进化的方法 |
-
2020
- 2020-01-31 CN CN202080026983.XA patent/CN113924115A/zh active Pending
- 2020-01-31 KR KR1020217027458A patent/KR20210130158A/ko active Search and Examination
- 2020-01-31 AU AU2020216480A patent/AU2020216480A1/en active Pending
- 2020-01-31 CA CA3128230A patent/CA3128230A1/en active Pending
- 2020-01-31 WO PCT/US2020/016273 patent/WO2020160508A1/en unknown
- 2020-01-31 JP JP2021544346A patent/JP2022523719A/ja active Pending
- 2020-01-31 US US17/427,513 patent/US20230193315A1/en active Pending
- 2020-01-31 EP EP20747744.9A patent/EP3917566A4/en active Pending
-
2021
- 2021-06-02 US US17/337,341 patent/US11459558B2/en active Active
-
2022
- 2022-08-24 US US17/822,111 patent/US20230119163A1/en active Pending
-
2023
- 2023-01-27 US US18/160,804 patent/US20230287405A1/en active Pending
- 2023-01-27 US US18/160,796 patent/US20230287404A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3917566A1 (en) | 2021-12-08 |
CN113924115A (zh) | 2022-01-11 |
US20210348160A1 (en) | 2021-11-11 |
KR20210130158A (ko) | 2021-10-29 |
US20230193315A1 (en) | 2023-06-22 |
US20230287404A1 (en) | 2023-09-14 |
WO2020160508A8 (en) | 2020-12-17 |
US11459558B2 (en) | 2022-10-04 |
AU2020216480A1 (en) | 2021-09-09 |
EP3917566A4 (en) | 2022-10-26 |
US20230119163A1 (en) | 2023-04-20 |
WO2020160508A1 (en) | 2020-08-06 |
CA3128230A1 (en) | 2020-08-06 |
US20230287405A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230287404A1 (en) | Methods for using transcription-dependent directed evolution of aav capsids | |
US11866462B2 (en) | Recombinant adeno-associated viral vectors | |
JP6921788B2 (ja) | アデノ随伴ウイルスプラスミド及びベクター | |
JP6363958B2 (ja) | Aav変異体 | |
JP6619454B2 (ja) | キャプシド | |
Vandenberghe et al. | Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing | |
EP3558393A2 (en) | Adeno associated viral vectors | |
KR20180091863A (ko) | 임상적 사용에 적합한 무혈청 현탁 세포 배양 시스템에서 재조합 아데노-관련 바이러스(aav) 벡터를 생성하기 위한 확장가능한 방법 | |
JP2011067212A (ja) | ハイブリッドウイルス粒子とその製造方法 | |
JP2001517071A (ja) | 組換えaavビリオン産生における使用のための補助機能 | |
JP2022544004A (ja) | 操作された核酸調節エレメントならびにその使用方法 | |
WO2020218419A1 (ja) | 脳に指向性を有するaav変異体 | |
JP2022547197A (ja) | アデノ随伴ウイルス(aav)の生体内分布の変更に向けた、aavとaav受容体(aavr)との間の相互作用を調節するための方法および組成物 | |
CN113874385A (zh) | 突变的腺相关病毒衣壳蛋白、包含该蛋白的aav颗粒和肝定向aav载体基因治疗 | |
CN114269935A (zh) | 用于治疗婴儿贝敦氏病的鞘内和静脉内组合基因疗法 | |
JP6473438B2 (ja) | プロモーター組成物 | |
US20220064668A1 (en) | Modified adeno-associated viral vectors for use in genetic engineering | |
AU2016202153A1 (en) | Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV in insect cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211004 |
|
RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20230110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230110 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230127 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240408 |